Skip to content

Advertisement

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact us so we can address the problem.

Biomarkers and clonality before and after treatment

  • 1
Retrovirology201411 (Suppl 1) :O31

https://doi.org/10.1186/1742-4690-11-S1-O31

  • Published:

Keywords

  • Interferon
  • Zidovudine
  • Therapeutic Decision
  • Interferon Alpha
  • Routine Testing

Adult T-cell leukemia-lymphoma (ATLL) is a disease with dismal prognosis urging new therapies. Few biomarkers have been identified to predict disease outcome in ATLL, however, routine testing for these is not widely available. The first line treatment option for ATLL can vary according to disease subtype, investigator’s choice, or institutional practices. For instance, experience at some centers suggest that there are patients with ATLL who can benefit from zidovudine (AZT)/interferon alpha (IFNα) therapy without requiring chemotherapy upfront. It has been reported that p53 gene alterations or MUM-/IRF-4 expression status may influence response to AZT/IFNα. More recently, the use of the anti-CD30 monoclonal antibody brentuximab vedotin is being advocated for the treatment of CD30+ T-cell malignancies, including ATLL. Therefore, establishing biomarkers that can help guide therapeutic decisions for ATLL would be ideal. Updated results and the usefulness of testing for some of these biomarkers will be discussed.

Authors’ Affiliations

(1)
Division of Hematology-Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA

Copyright

© Ramos; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement